Business
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; O...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson\nVinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 09, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending acquisition. On April 8, 2026, Realbotix announced that it has delivered its first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that allows the robot to recognize returning users, recall previous conversations, and track engagement. Vinci, Realbotix's AI vision and eye tracking technology, incorporates in-eye cameras that provide real-time environmental awareness. With the ability to maintain eye contact, Vinci robots can recognize people they have previously interacted with, recall prior conversations, and continue them. Vinci can be added to any Realbotix robot model. Vinci-enabled robots facilitate AI data collection from the humans they interact with, including the following: Identity layer (who is interacting);Behavioral tracking (what they are doing);Emotional signal capture (how they respond and are feeling); andEngagement analytics over time (clinical trials and data comparison). As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. This communication includes information regarding Realbotix, a company that Onconetix has agreed to acquire, and is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected informatio...